ECO Synthesis Launch In 2025 Will Unlock Pharma Contracts

Published
29 Mar 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$7.08
56.9% undervalued intrinsic discount
08 Aug
US$3.05
Loading
1Y
8.2%
7D
6.6%

Author's Valuation

US$7.1

56.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 53%

Shared on24 Apr 25
Fair value Decreased 24%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 13%

AnalystConsensusTarget has decreased revenue growth from 33.4% to 23.1%, increased future PE multiple from 54.4x to 63.7x and decreased shares outstanding growth rate from 0.2% to 0.1%.